Strains of bacteria resistant to beta-lactam antibiotics have been increasing in number and are becoming troublesome in clinical medicine. The in vitro antibacterial activity of amoxicillin combined with clavulanic acid was determined on selected ampicillin-resistant clinical isolates. Synergistic effects were produced by amoxicillin with clavulanic acid against ampicillin-resistant strains of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, and Bacteroides fragilis. Inhibition of the beta-lactamases produced by the ampicillin-resistant strains was confirmed, especially against the penicillinases mediated by the R factor and the cephalosporinases produced by P. vulgaris and B. fragilis. The inhibitory effect of clavulanic acid against betalactamases was irreversible because of the high affinity of clavulanic acid to the enzymes.
Strains of bacteria resistant to beta-lactam antibiotics have been increasing in number and are becoming troublesome in clinical medicine. The in vitro antibacterial activity of amoxicillin combined with clavulanic acid was determined on selected ampicillin-resistant clinical isolates. Synergistic effects were produced by amoxicillin with clavulanic acid against ampicillin-resistant strains of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, and Bacteroides fragilis. Inhibition of the beta-lactamases produced by the ampicillin-resistant strains was confirmed, especially against the penicillinases mediated by the R factor and the cephalosporinases produced by P. vulgaris and B. fragilis. The inhibitory effect of clavulanic acid against betalactamases was irreversible because of the high affinity of clavulanic acid to the enzymes.
Bacterial strains resistant to beta-lactam antibiotics have been increasing in number. The resistance of these bacteria is due mainly to the production of beta-lactamase (1), and newer semisynthetic beta-lactam antibiotics, i.e., cefuroxime (8) and cefoxitin (12) , resistant to betalactamase have been developed. Clavulanic acid (CVA) (2, 10) and CP-45899 (4) were found to be beta-lactamase inhibitors, although they have poor antibacterial activity. Combination of these products with other beta-lactam antibiotics possessing high antibacterial activity but less stability to beta-lactamase will be a new approach to chemotherapy against resistant strains capable of producing beta-lactamase. This paper deals with the combined antibacterial activity of amoxicillin (AMC) with CVA against ampicillin (APC)-resistant strains ofbacteria. 12 ,000 rpm in the cold, and streptomycin (1 g/5 g of wet volume) was added to the supernatant which was dialyzed overnight against distilled water. Penicillinase (PCase) was purified by diethylaminoethyl-cellulose column chromatography, and cephalosporinase (CSase) was purified by carboxymethyl-Sephadex C-50 column chromatography by the method described previously (11) . The partially purified enzymes, further purified on Sephadex G-100 columns (11) , were used for the following studies.
MATERIALS AND METHODS
Beta-lactamase assay. Beta-lactamase activity was determined by a direct spectrophotometric 
RESULTS
Combined antibacterial activity of AMC with CVA. The combined antibacterial effect of AMC with CVA was studied by determination of bactericidal effect against APC-resistant E. coli ML5005, K. pneumoniae ML5006, P. mirabilis ML5007, and P. vulgaris ML5008 strains by viable count studies (Fig. 1) . When the final concentration of 1 ,ug of CVA per ml was added to AMC, the bactericidal activity of the combined drugs was found to be low; the growth of bacteria was greatly reduced when 5 or 10 ,ug of CVA per ml was used, indicating the high bactericidal activity of the combination of AMC with CVA. Beta-lactamase produced by resistant strains is classified into two groups, PCase and CSase. The typical PCase mediated by R factor in gram-negative bacteria is divided into four types, i.e., I, II, III, and IV (3, 11, 13, 14). On the contrary, CSase produced by gram-negative bacteria is specified by the chromosome. The combined antibacterial activity of AMC with CVA was found to be high against APCresistant strains due to the production of Rmediated PCase types I, II, III, and IV. In contrast, the synergistic effect of CVA was rather low on the strains capable of producing CSase, except P. vulgaris and Bacteroides fragilis ( Table 1) .
Inhibition of beta-lactamase activity. The inhibitory activity of CVA against beta-lacta- mases produced from gram-negative bacteria was found against all PCases from R-bearing bacteria, a new type of beta-lactamase from the strain of Pseudomonas cepacia GN11164, and two CSases from the strains of P. vulgaris GN7961 and B. fragilis GN11478 ( Table 2 ). The antibacterial activity of AMC combined with CVA on whole bacterial cells corresponded to that of the inhibition effect against beta-lactamases from intact cells of bacteria. Kinetic studies of beta-lactamase inhibition by CVA and cloxacillin are shown in Fig. 2 . The Km's of cephalothin against E. coli ML1410/ Rms422 and E. coli ML1410/Rms423 were 111.1 and 153.8 ,M, respectively. The Ki's of CVA were 0.32 and 0.40 ,M, respectively. The Ki's of a Beta-lactamase activity was assayed by spectrophotometric method, and cephalothin (100 uM) was used as a substrate. Inhibition of beta-lactamase activity was expressed by (A -B)/A (%). A, Beta-lactamase activity without inhibitor; B, beta-lactamase activity with inhibitor.
b Ris422, Rms423, and Rxns421 were isolated from strains of E. coli GN9290, K. pneumoniae GN9619, and P. rettgeri GN4762, respectively.
'Beta-lactamase produced by P. cepacia GN11164 is a new type of enzyme (Hirai et al., submitted for publication). cloxacillin were 4.85 and 7.5 uM, respectively. The affinity of CVA to both beta-lactamases was found to be higher than that of cloxacillin, and the inhibitory property of CVA was found to be irreversible. DISCUSSION This paper confirms the synergistic antibacterial activity of AMC with CVA against APCresistant strains of E. coli, K. pneumoniae, P. mirabilis, P. vulgaris, and B. fragilis that owed their resistance to the production of beta-lactamase. In a previous study (10) , CVA had a potent inhibitory activity against TEM-type of betalactamase produced by E. coli R+ strain. In this study, CVA had an inhibitory effect against not only PCase produced from the APC-resistant R+ strains but also CSase from strains ofP. vulgaris and B. fragilis. The synergistic antibacterial activity of AMC with CVA was recognized on the species of bacteria mentioned above by the addition of a small amount of CVA.
There were some organisms in which the combined antibacterial activity of AMC with CVA was not recognized, e.g., strains ofPseudomonas aeruginosa, Enterobacter cloacae, Proteus morganii, Proteus rettgeri, and Serratia marcescens. This result was probably due to the poor inhibitory effect of AMC against these strains (9) .
In this report, we selected AMC as a target antibiotic of CVA because of its broad antibacterial activity but relatively low stability to betalactamase. Therefore, the combined antibacterial activity ofbeta-lactam antibiotics other than AMC with CVA may be found against APCresistant strains, as reported by earlier studies (6, 9) .
